P3 Health Partners' Q3 revenue down 5% due to payer rationalization

P3 Health Partners

13/11/2025 22:42

Overview

P3 Health Q3 revenue falls 5% yr/yr due to network rationalization

Adjusted EBITDA loss for Q3 was $45.9 mln

Company aims for $120-$170 mln EBITDA expansion, targeting profitability by 2026

Outlook

P3 Health Partners expects 2025 revenue between $1.4 bln and $1.45 bln

Company anticipates 2025 medical margin of $67 mln to $82 mln

P3 projects 2025 adjusted EBITDA loss of $110 mln to $95 mln

Result Drivers

CARE ENABLEMENT MODEL - Expansion of Care Enablement Model drove positive momentum in core business, per CEO Aric Coffman

NETWORK RATIONALIZATION - Revenue decline attributed to intentional reduction in membership due to network and payer rationalization

STABLE MEDICAL COSTS - Medical cost trends remained stable, normalized for prior-year adjustments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Total revenue
$345.3 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for P3 Health Partners Inc is $13.00, about 46.2% above its November 13 closing price of $7.00

Press Release: ID:nBw40lvbwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)